ETF Holdings Breakdown of TRML

TRML institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	20,032	USD 959,533
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	16,139	USD 773,058
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	16,139	USD 773,058
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	418	USD 20,022 0.0%
Total =		52,728	USD 2,525,671

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with TRML

Truist Financial Downgrades Tourmaline Bio (NASDAQ:TRML) to Hold

Tourmaline Bio (NASDAQ:TRML – Get Free Report) was downgraded by equities research analysts at Truist Financial from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. They presently have a $48.00 price target on the stock, down from their previous price target of […] - 2025-09-11 05:14:52

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $50.14 Average Target Price from Analysts

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average […] - 2025-09-10 02:32:51

Tourmaline Bio Agrees To Be Acquired By Novartis In $1.4 Bln Deal; Stock Up

(RTTNews) - Tourmaline Bio Inc. (TRML) announced Tuesday that it has agreed to be acquired by Novartis AG (NVS, NOVN.SW) for $48.00 per share in cash at closing, representing a total equity value of about $1.4 billion. The deal price represents a premium of 59% to Tourmalines clo - 2025-09-09 02:28:03

Federated Hermes Inc. Buys 120,322 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

Federated Hermes Inc. increased its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 13,036.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 121,245 shares of the company’s stock after acquiring an additional 120,322 shares during the quarter. Federated Hermes Inc.’s […] - 2025-08-06 05:13:00

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Consensus PT from Analysts

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has received an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last […] - 2025-06-27 02:37:04

GAMMA Investing LLC Grows Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)

GAMMA Investing LLC grew its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 4,481.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 7,514 shares of the company’s stock after acquiring an additional 7,350 shares during the quarter. GAMMA Investing LLC’s holdings in Tourmaline Bio were worth $114,000 at the […] - 2025-06-24 04:46:55

SG Americas Securities LLC Has $550,000 Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

SG Americas Securities LLC lifted its position in Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 3.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,180 shares of the company’s stock after buying an additional 1,368 shares during the quarter. SG Americas […] - 2025-06-23 04:58:58

California State Teachers Retirement System Has $213,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)

California State Teachers Retirement System increased its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 527.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 10,505 shares of the company’s stock after buying an additional 8,832 shares during the quarter. California State Teachers Retirement System’s holdings in Tourmaline Bio were […] - 2025-06-13 05:02:51

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Consensus PT from Brokerages

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the […] - 2025-06-02 03:09:00

Millennium Management LLC Has $7.40 Million Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)

Millennium Management LLC lowered its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 28.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 364,658 shares of the company’s stock after selling 144,757 shares during the quarter. Millennium […] - 2025-05-27 04:48:57

Head-To-Head Analysis: Tourmaline Bio (NASDAQ:TRML) vs. enGene (NASDAQ:ENGN)

Tourmaline Bio (NASDAQ:TRML – Get Free Report) and enGene (NASDAQ:ENGN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Institutional & Insider Ownership 91.9% of Tourmaline Bio […] - 2025-05-14 02:20:48

Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Target Price at $49.33

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last […] - 2025-05-08 02:04:55

Barclays PLC Acquires 26,733 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

Barclays PLC grew its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 84.0% during the fourth quarter, Holdings Channel reports. The firm owned 58,566 shares of the company’s stock after purchasing an additional 26,733 shares during the period. Barclays PLC’s holdings in Tourmaline Bio were worth $1,187,000 as of its most […] - 2025-05-05 05:18:49

Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from Analysts at Chardan Capital

Stock analysts at Chardan Capital began coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a report issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 304.16% from the company’s current price. […] - 2025-04-25 04:24:47

Vanguard Group Inc. Acquires 43,652 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

Vanguard Group Inc. boosted its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 4.1% in the 4th quarter, HoldingsChannel reports. The fund owned 1,106,125 shares of the company’s stock after buying an additional 43,652 shares during the quarter. Vanguard Group Inc.’s holdings in Tourmaline Bio were worth $22,432,000 at the end […] - 2025-04-16 04:28:51

Head to Head Survey: Tourmaline Bio (NASDAQ:TRML) vs. Vaxcyte (NASDAQ:PCVX)

Vaxcyte (NASDAQ:PCVX – Get Free Report) and Tourmaline Bio (NASDAQ:TRML – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Profitability This table compares Vaxcyte and Tourmaline Bio’s net […] - 2025-02-21 04:34:51

Back to Listing

Disclaimer